Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?
Section snippets
Conflict of interest statement
None declared.
References (11)
- et al.
Reimbursement of effective new anticancer agents: we should change the process to ensure wide access to patients
Lancet Oncol
(2006) - et al.
Anticancer drug discovery and development throughout the world
J Clin Oncol
(2002) - et al.
The benefit of participating to clinical research
Breast Cancer Res Treat
(2005) - et al.
AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer
Int J Gynecol Cancer
(2005) The burden of scientific progress: growing inequalities in the delivery of cancer care
Acta Oncol
(2006)
There are more references available in the full text version of this article.
Cited by (15)
Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
2021, Clinical Colorectal CancerCitation Excerpt :Multinational trials, such as SCOT, have several advantages. Patient recruitment is expedited, patients from several countries are given the opportunity to participate in research, and the generalizability of clinical results is widened.11,12 The transferability of cost-effectiveness estimates among countries, however, is not straightforward.
Clinical research as a strategy for health development
2012, Revista da Associacao Medica BrasileiraBuilding research capacity and clinical trials in developing countries
2010, The Lancet OncologyThe patient’s safety and access to experimental drugs after the termination of clinical trials: regulations and trends
2018, European Journal of Clinical PharmacologyHuman dignity as a basis for providing post-trial access to healthcare for research participants: a South African perspective
2018, Medicine, Health Care and PhilosophyRandomized clinical trials on breast cancer in Nigeria and other developing countries: Challenges and constraints
2017, Perioperative Inflammation as Triggering Origin of Metastasis Development
Copyright © 2006 Elsevier Ltd. All rights reserved.